Corestemchemon Inc
166480
Company Profile
Business description
Corestemchemon Inc is a biopharmaceutical company that researches and commercializes stem cell technology. It has developed NEURONATA-R inj., a stem cell therapy for Lou Gehrig's disease which is a rare incurable disease, for the first ALS treatment. Its stem cell therapeutics for Lou Gehrig's disease have a pipeline of incurable diseases such as lupus, multiple system atrophy, and osteoarthritis, and plans to preoccupy the market by focusing on developing therapies for rare incurable diseases based on a development success reference of stem cell therapy for the Lou Gehrig's disease.
Contact
Pangyo 255 beongil 24 I & C Building, 2nd Floor
yeonggi-do, Bundang-gu
Seongnam
Seoul13486
KORT: +82 24973711
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
371
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.50 | 22.70 | 0.26% |
| CAC 40 | 7,779.72 | 8.38 | -0.11% |
| DAX 40 | 23,933.23 | 104.96 | -0.44% |
| Dow JONES (US) | 42,215.73 | 117.03 | 0.28% |
| FTSE 100 | 8,716.45 | 9.56 | -0.11% |
| HKSE | 23,207.37 | 366.01 | -1.55% |
| NASDAQ | 19,175.87 | 74.93 | 0.39% |
| Nikkei 225 | 38,099.69 | 333.29 | -0.87% |
| NZX 50 Index | 12,418.89 | 137.58 | 1.12% |
| S&P 500 | 5,912.17 | 23.62 | 0.40% |
| S&P/ASX 200 | 8,435.70 | 25.90 | 0.31% |
| SSE Composite Index | 3,353.10 | 10.34 | -0.31% |